A need for evidence-based clinical practice guidelines for the use of heparins in the elderly

Isabelle Gouin-Thibault1,2, Virginie Siguret1,2, Eric Pautas2,31Assistance Publique Hôpitaux de Paris, Laboratoire d’Hématologie, Hôpital Charles Foix, Paris, France; 2Université Paris Descartes, INSERM U, Paris, France; 3Assistance Publique H&...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Isabelle Gouin-Thibault, Virginie Siguret, Eric Pautas
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://doaj.org/article/3d2cee01e36042088fedf8a0c07a5fea
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3d2cee01e36042088fedf8a0c07a5fea
record_format dspace
spelling oai:doaj.org-article:3d2cee01e36042088fedf8a0c07a5fea2021-12-02T00:30:05ZA need for evidence-based clinical practice guidelines for the use of heparins in the elderly1178-1998https://doaj.org/article/3d2cee01e36042088fedf8a0c07a5fea2010-04-01T00:00:00Zhttps://www.dovepress.com/a-need-for-evidence-based-clinical-practice-guidelines-for-the-use-of--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Isabelle Gouin-Thibault1,2, Virginie Siguret1,2, Eric Pautas2,31Assistance Publique Hôpitaux de Paris, Laboratoire d’Hématologie, Hôpital Charles Foix, Paris, France; 2Université Paris Descartes, INSERM U, Paris, France; 3Assistance Publique Hôpitaux de Paris, Unité de Gériatrie Aiguë, Hôpital Charles Foix, Paris, FranceAbstract: Low-molecular-weight heparins (LMWHs) have been widely studied in pivotal clinical trials or in several meta-analyses. However, the safety and optimal use of LMWHs in high-risk patients such as the very elderly remains uncertain since these patients are usually excluded from clinical trials. In terms of LMWHs in the elderly, the main concerns are renal failure and the risk of accumulation. A clinical approach consisting of a LMWH dose reduction in the elderly should be considered with great caution in terms of efficacy, since it has been tested neither in the treatment of VTE nor in VTE prophylaxis. If monitoring is considered in patients receiving therapeutic dose LMWHs, appropriate target ranges for peak anti-Xa activity levels should be used and so far, no anti-Xa activity-based guidelines have been issued. Moreover, no data support any laboratory monitoring in elderly patients treated with prophylactic dose LMWHs.Keywords: elderly patients, low-molecular-weight heparin, renal insufficiency, evidence-based medicineIsabelle Gouin-ThibaultVirginie SiguretEric PautasDove Medical Pressarticleelderlylow molecular weight heparinsGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 5, Pp 119-121 (2010)
institution DOAJ
collection DOAJ
language EN
topic elderly
low molecular weight heparins
Geriatrics
RC952-954.6
spellingShingle elderly
low molecular weight heparins
Geriatrics
RC952-954.6
Isabelle Gouin-Thibault
Virginie Siguret
Eric Pautas
A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
description Isabelle Gouin-Thibault1,2, Virginie Siguret1,2, Eric Pautas2,31Assistance Publique Hôpitaux de Paris, Laboratoire d’Hématologie, Hôpital Charles Foix, Paris, France; 2Université Paris Descartes, INSERM U, Paris, France; 3Assistance Publique Hôpitaux de Paris, Unité de Gériatrie Aiguë, Hôpital Charles Foix, Paris, FranceAbstract: Low-molecular-weight heparins (LMWHs) have been widely studied in pivotal clinical trials or in several meta-analyses. However, the safety and optimal use of LMWHs in high-risk patients such as the very elderly remains uncertain since these patients are usually excluded from clinical trials. In terms of LMWHs in the elderly, the main concerns are renal failure and the risk of accumulation. A clinical approach consisting of a LMWH dose reduction in the elderly should be considered with great caution in terms of efficacy, since it has been tested neither in the treatment of VTE nor in VTE prophylaxis. If monitoring is considered in patients receiving therapeutic dose LMWHs, appropriate target ranges for peak anti-Xa activity levels should be used and so far, no anti-Xa activity-based guidelines have been issued. Moreover, no data support any laboratory monitoring in elderly patients treated with prophylactic dose LMWHs.Keywords: elderly patients, low-molecular-weight heparin, renal insufficiency, evidence-based medicine
format article
author Isabelle Gouin-Thibault
Virginie Siguret
Eric Pautas
author_facet Isabelle Gouin-Thibault
Virginie Siguret
Eric Pautas
author_sort Isabelle Gouin-Thibault
title A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
title_short A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
title_full A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
title_fullStr A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
title_full_unstemmed A need for evidence-based clinical practice guidelines for the use of heparins in the elderly
title_sort need for evidence-based clinical practice guidelines for the use of heparins in the elderly
publisher Dove Medical Press
publishDate 2010
url https://doaj.org/article/3d2cee01e36042088fedf8a0c07a5fea
work_keys_str_mv AT isabellegouinthibault aneedforevidencebasedclinicalpracticeguidelinesfortheuseofheparinsintheelderly
AT virginiesiguret aneedforevidencebasedclinicalpracticeguidelinesfortheuseofheparinsintheelderly
AT ericpautas aneedforevidencebasedclinicalpracticeguidelinesfortheuseofheparinsintheelderly
AT isabellegouinthibault needforevidencebasedclinicalpracticeguidelinesfortheuseofheparinsintheelderly
AT virginiesiguret needforevidencebasedclinicalpracticeguidelinesfortheuseofheparinsintheelderly
AT ericpautas needforevidencebasedclinicalpracticeguidelinesfortheuseofheparinsintheelderly
_version_ 1718403670259793920